ATYR · aTYR PHARMA INC

$0.52 -0.04 (-6.64%)

Market Cap

$54.83M

98.09M

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

Fiscal 2025

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Sanjay Shukla	M.D., M.S. President and CEO	$638,977	—	—	$2,595,200	$210,862	$11,214	$3,456,253
Jill Broadfoot	Chief Financial Officer	$471,790	—	—	$713,680	$113,229	$11,214	$1,309,913
Nancy E. Denyes	—	$451,570	—	—	$713,680	$108,377	$11,214	$1,284,841

Fiscal 2024

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Sanjay Shukla	M.D., M.S. President and CEO	$580,887	—	—	$641,760	$246,877	$10,998	$1,480,522
Jill Broadfoot	Chief Financial Officer	$428,899	—	—	$160,440	$145,826	$10,998	$746,163
Nancy E. Denyes	—	$410,517	—	—	$160,440	$139,576	$18,772	$729,305
General Counsel	—	$410,517	—	—	$160,440	$139,576	$18,772	$729,305

Fiscal 2023

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Sanjay Shukla	M.D., M.S. President and CEO	$561,243	—	—	$532,341	$196,435	$10,506	$1,300,525
Jill Broadfoot	Chief Financial Officer	$414,395	—	—	$133,084	$116,031	$14,327	$677,837
Nancy E. Denyes	—	$396,635	—	—	$133,084	$111,058	$10,506	$651,283
General Counsel	—	$396,635	—	—	$133,084	$111,058	$10,506	$651,283

Fiscal 2022

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Sanjay Shukla	M.D., M.S. President and CEO	$561,243	—	$229,080	$1,386,876	$224,500	$9,736	$2,411,435
Jill Broadfoot	Chief Financial Officer	$414,395	—	$82,800	$274,076	$132,610	$9,612	$913,493
General Counsel	—	$396,635	—	$59,340	$266,053	$126,925	$8,575	$857,528

Fiscal 2021

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Sanjay Shukla	M.D., M.S. President and CEO	$510,221	—	—	$1,076,297	$293,377	$12,813	$1,892,708
Jill Broadfoot	Chief Financial Officer	$376,723	—	—	$355,683	$173,282	$11,755	$917,443
Nancy E. Denyes	—	$360,577	—	—	$353,702	$165,876	$11,133	$891,288

Fiscal 2020

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Sanjay Shukla	M.D., M.S. President and CEO	$470,250	—	—	$381,811	$223,369	$8,427	$1,083,857
Jill Broadfoot	Chief Financial Officer	$365,750	—	—	$182,671	$138,985	$11,374	$698,780
Nancy E. Denyes	—	$350,075	—	—	$148,121	$116,400	$10,661	$625,257
General Counsel	—	$350,075	—	—	$148,121	$116,400	$10,661	$625,257

Fiscal 2019

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Sanjay Shukla	M.D., M.S. President and CEO	$450,000	—	$25,860	$82,400	$95,625	$10,076	$663,961
Jill Broadfoot	Chief Financial Officer	$350,000	—	$12,930	$20,600	$59,500	$11,594	$454,624
Nancy E. Denyes	—	$335,000	—	—	$51,500	$49,831	$12,932	$449,263
General Counsel	—	$335,000	—	—	$51,500	$49,831	$12,932	$449,263

Fiscal 2018

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Sanjay Shukla	M.D., M.S. President and Chief Executive Officer	$450,000	—	—	$780,000	$140,549	$9,916	$1,380,465
Jill Broadfoot	Chief Financial Officer	$148,526	—	—	$121,880	$58,324	$5,393	$334,123

Executive changes

Person	Role	Change	Effective	Filed
Sara L. Zaknoen, M.D.	Class I director	Appointed	2025-05-01	2025-05-06
Paul Schimmel, Ph.D.	Class I director	Appointed	2025-05-01	2025-05-06
Eric Benevich	Class II director	Appointed	2024-12-10	2024-12-12
Sanjay S. Shukla, M.D., M.S.	Class III director	Appointed	2024-05-22	2024-05-29
Svetlana Lucas, Ph.D.	Class III director	Appointed	2024-05-22	2024-05-29
Jane A. Gross, Ph.D.	Class II director	Appointed	2023-05-17	2023-05-19
Timothy P. Coughlin	Class II director	Appointed	2023-05-17	2023-05-19
Paul Schimmel	Class I director	Appointed	2022-04-26	2022-04-29
Sara L. Zaknoen	Class I director	Appointed	2022-04-26	2022-04-29
John K. Clarke	Class I director	Appointed	2022-04-26	2022-04-29

Key facts CIK 1339970 CUSIP 002120202 13F (30d) 87 filings 85 filers Visit website Investor relations